RxDoctor Payments Data

Deborah Dover, MD

Neurology · Great Falls, MTNPI 1972504850

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 58.6% of the total. Reporting peaked in 2019 at $10,064 and has fallen 78.2% since, to $2,190 in 2025.

$19,355in general payments, 2019–2025

Across 539 payments — averaging $35.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$11K
  • AbbVie$2K
  • Novartis$1K
  • Medtronic$741
  • Bristol Myers Squibb$543
  • Biogen$466
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$3,65019%
  • Speaking & faculty fees$4,92725%
  • Travel & lodging$1,8169%
  • Food & beverage$8,80645%
  • Education$1561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,355 in reported general payments places this provider in the 85th percentile of 48 neurology providers in Montana.

See all neurology providers in Montana

Medicare billing

Part B allowed, 2024
$116,570
Medicare patients
228
Services billed
11,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab12$104,777
CopaxoneGlatiramer Acetate17$97,870
Avonex Pen (4 Pack)Interferon Beta-1a12$96,437
Aimovig AutoinjectorErenumab-Aooe74$58,494
GlatopaGlatiramer Acetate33$54,194
Nurtec OdtRimegepant Sulfate32$43,093
AptiomEslicarbazepine Acetate52$32,690
TopamaxTopiramate28$28,475
Emgality PenGalcanezumab-Gnlm40$28,128
QuliptaAtogepant21$21,816
Dalfampridine ErDalfampridine28$14,586
Acetazolamide13$8,769
Lamotrigine ErLamotrigine22$8,195
FingolimodFingolimod Hcl12$7,400
Carbamazepine ErCarbamazepine105$7,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$11,340$97,87017 claims
PfizerNurtec Odt$44$43,09332 claims
Sunovion Pharmaceuticals Inc.Aptiom$87$32,69052 claims
AbbVieQulipta$1,688$21,81621 claims
Upsher-smith Laboratories LLCTopiramate$11$1,53788 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 neurology providers in Montana.

Other neurology in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →